Omalizumab in Combination with Subcutaneous Immunotherapy for the Treatment of Multiple Allergies Associated with Attention-deficit/hyperactivity Disorder: a Case Report and a Literature Review

Overview

Journal Front Pharmacol

Date 2024 Jun 18

PMID 38887551

Authors

Bo Ding

Yanming Lu

Affiliations

Soon will be listed here.

Abstract

We describe the case of a 10-year-old boy with asthma (AS), accompanied by allergic rhinitis (AR), food allergy (FA), and combined attention-deficit/hyperactivity disorder (ADHD), who was treated at Shanghai Renji Hospital on 11 July 2020. The efficiency of the previous treatment with salmeterol/ticlosone was poor. Treatment with montelukast sodium resulted in development of neurological symptoms. Treatment with omalizumab in combination with subcutaneous immunotherapy (SCIT) was then initiated in our department based on anti-asthmatic therapy. Symptoms of asthma were completely controlled, and FA and AR symptoms improved. The treatment regimen led to a significant improvement in ADHD symptoms and the overall quality of life of the patient. The literature search was done in the PubMed database using "attention deficit/hyperactivity disorder/ADHD" and "asthma" as keywords, and we identified 47 relevant articles. In conclusion, our results show that treating asthma with omalizumab in combination with salmeterol/ticlosone and SCIT is efficient in controlling symptoms of multiple allergies and may lead to the improvement in ADHD symptoms and the overall quality of life of pediatric patients with ADHD. While current studies suggest that allergic diseases are closely related to ADHD, there is still a lack of studies or case reports of complete treatment protocols to provide clinical clues for management of the disease.

Citing Articles

Early-life IL-4 administration induces long-term changes in microglia in the cerebellum and prefrontal cortex.

Ferreira P, Lebre C, Costa J, Amaral F, Ferreira R, Martinho F J Neurochem. 2024; 169(1):e16266.

PMID: 39676699 PMC: 11647562. DOI: 10.1111/jnc.16266.

References

Pelsser L, Buitelaar J, Savelkoul H . ADHD as a (non) allergic hypersensitivity disorder: a hypothesis. Pediatr Allergy Immunol. 2008; 20(2):107-12. DOI: 10.1111/j.1399-3038.2008.00749.x. View

Kuehr J, Brauburger J, Zielen S, Schauer U, Kamin W, von Berg A . Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis. J Allergy Clin Immunol. 2002; 109(2):274-80. DOI: 10.1067/mai.2002.121949. View

Wang J, Zhou Y, Zhang H, Hu L, Liu J, Wang L . Pathogenesis of allergic diseases and implications for therapeutic interventions. Signal Transduct Target Ther. 2023; 8(1):138. PMC: 10039055. DOI: 10.1038/s41392-023-01344-4. View

Kay A . Allergy and allergic diseases. First of two parts. N Engl J Med. 2001; 344(1):30-7. DOI: 10.1056/NEJM200101043440106. View

Crosson T, Wang J, Doyle B, Merrison H, Balood M, Parrin A . FcεR1-expressing nociceptors trigger allergic airway inflammation. J Allergy Clin Immunol. 2021; 147(6):2330-2342. PMC: 9004488. DOI: 10.1016/j.jaci.2020.12.644. View

Jiang X, Shen C, Li K, Ji Y, Li S, Jiang F . [Impact of allergic airway diseases on risk of attention deficit hyperactivity disorder in school-age children]. Zhonghua Er Ke Za Zhi. 2017; 55(7):509-513. DOI: 10.3760/cma.j.issn.0578-1310.2017.07.008. View

Sztafinska A, Jerzynska J, Stelmach W, Woicka-Kolejwa K, Stelmach I . Quality of life in asthmatic children and their caregivers after two-year treatment with omalizumab, a real-life study. Postepy Dermatol Alergol. 2018; 34(5):439-447. PMC: 5831278. DOI: 10.5114/ada.2017.71109. View

Esteban-Gorgojo I, Gorgojo M, Sastre J, Quirce S . Food allergy as an asthma comorbidity in children and adolescents: a practical approach through a real-world study. Allergol Immunopathol (Madr). 2021; 49(1):68-78. DOI: 10.15586/aei.v49i1.19. View

Sun S, Kuja-Halkola R, Chang Z, Cortese S, Almqvist C, Larsson H . Familial liability to asthma and ADHD: A Swedish national register-based study. JCPP Adv. 2023; 1(4):e12044. PMC: 10242819. DOI: 10.1002/jcv2.12044. View

10.

Chang J, Su K, Mondelli V, Pariante C . Cortisol and inflammatory biomarker levels in youths with attention deficit hyperactivity disorder (ADHD): evidence from a systematic review with meta-analysis. Transl Psychiatry. 2021; 11(1):430. PMC: 8377148. DOI: 10.1038/s41398-021-01550-0. View

11.

. [Chinese guidelines for the diagnosis and treatment of allergic asthma (2019, the first edition)]. Zhonghua Nei Ke Za Zhi. 2019; 58(9):636-655. DOI: 10.3760/cma.j.issn.0578-1426.2019.09.004. View

12.

Holmberg K, Lundholm C, Anckarsater H, Larsson H, Almqvist C . Impact of asthma medication and familial factors on the association between childhood asthma and attention-deficit/hyperactivity disorder: a combined twin- and register-based study: Epidemiology of Allergic Disease. Clin Exp Allergy. 2015; 45(5):964-973. DOI: 10.1111/cea.12529. View

13.

van der Schans J, Pleiter J, De Vries T, Schuiling-Veninga C, Bos J, Hoekstra P . Association between medication prescription for atopic diseases and attention-deficit/hyperactivity disorder. Ann Allergy Asthma Immunol. 2016; 117(2):186-91. DOI: 10.1016/j.anai.2016.05.025. View

14.

Pfutzner W, Schuppe M . Use of biologics in allergen immunotherapy. Allergol Select. 2021; 5:108-118. PMC: 7901361. DOI: 10.5414/ALX02206E. View

15.

Bousquet P, Combescure C, Neukirch F, Klossek J, Mechin H, Daures J . Visual analog scales can assess the severity of rhinitis graded according to ARIA guidelines. Allergy. 2007; 62(4):367-72. DOI: 10.1111/j.1398-9995.2006.01276.x. View

16.

van der Kleij H, Charles N, Karimi K, Mao Y, Foster J, Janssen L . Evidence for neuronal expression of functional Fc (epsilon and gamma) receptors. J Allergy Clin Immunol. 2010; 125(3):757-60. PMC: 2839037. DOI: 10.1016/j.jaci.2009.10.054. View

17.

Cecchi L, DAmato G, Annesi-Maesano I . External exposome and allergic respiratory and skin diseases. J Allergy Clin Immunol. 2018; 141(3):846-857. DOI: 10.1016/j.jaci.2018.01.016. View

18.

Swanson J, Kraemer H, Hinshaw S, Arnold L, Conners C, Abikoff H . Clinical relevance of the primary findings of the MTA: success rates based on severity of ADHD and ODD symptoms at the end of treatment. J Am Acad Child Adolesc Psychiatry. 2001; 40(2):168-79. DOI: 10.1097/00004583-200102000-00011. View

19.

Leffa D, Torres I, Rohde L . A Review on the Role of Inflammation in Attention-Deficit/Hyperactivity Disorder. Neuroimmunomodulation. 2018; 25(5-6):328-333. DOI: 10.1159/000489635. View

20.

Hutyrova B, Bystron J . The effect of omalizumab treatment on severe allergic asthma and allergic comorbidities: real-life experience from the Czech Anti-IgE Registry. Postepy Dermatol Alergol. 2018; 35(5):510-515. PMC: 6232552. DOI: 10.5114/ada.2018.77243. View